# Internet Monitoring Services of FDA Related Products

Canonical: https://abierto.us/opportunities/75f40124q00348

- Solicitation number: 75F40124Q00348
- Notice type: Award notice (first published as combined synopsis and solicitation)
- Status: Awarded to S-3 Research LLC for $6,842,784.00
- Department: Department of Health and Human Services
- Agency: Food and Drug Administration
- Contracting office: FDA Office of Regulatory Affairs (75DLLR)
- NAICS: 541519 Other Computer Related Services
- Product or service code: DJ10 Security and Compliance support delivered as a service, by subscription, or service contract. Includes support of security policies/controls, processes, measuring compliance of relevant legal/compliance requirements, to include Section 508, and responding to security breaches. Also provides support for IT Security systems providing Continuous Diagnostics and Mitigation (CDM) for real-time Cyber Security and protection such as vulnerability scanning, managing firewalls, intrusion prevention systems, and security information and event management (SIEM). Includes Disaster Recovery (DR) services to support DR policy, process and means, dedicated failover facilities and perform DR testing.
- Place of performance: Silver Spring, Maryland
- County: Montgomery County (FIPS 24031). https://abierto.us/counties/montgomery-county-md-24031
- City: Silver Spring. https://abierto.us/cities/silver-spring-md-2472450
- First posted: July 8, 2024
- Last posted: October 1, 2024
- SAM.gov: https://sam.gov/workspace/contract/opp/778f8cd9399a48e2ae16075261337c2c/view

## Description

**AMENDMENT 2

Please see updated Attachment_A_SOW_Amendment2, Attachment_B_PricingExcelWorkbook_Amendment2, Attachment_C_SOL_RFQ_Amendment2, and QA_FDA OCI Internet Monitoring Services_75F40124Q00348 - The purpose of this amendment is to provide responses to questions submitted by interested vendors as well as revise ALL attachments associated.** FDA is responsible for regulating products to ensure the safety of foods, prescription and over-the-counter drugs, biological products such as vaccines and blood, medical devices, cosmetics, radiation-emitting products, and more.

Since 1993, Office of Criminal Investigation (OCI) has investigated thousands of criminal schemes involving the distribution of potentially dangerous FDA-regulated products.

These investigations have involved a wide variety of criminal conduct, including street level distribution of counterfeit, unapproved, and designer drugs, major organized illicit diversion of prescription drugs, fraudulent schemes involving ineffective AIDS, cancer, and Alzheimer cures, large scale product substitution conspiracies, application and clinical investigator fraud, and health frauds involving harmful FDA-regulated drugs and medical devices.

As FDA’s criminal law enforcement arm, OCI protects the American public by conducting criminal investigations of illegal activities involving FDA-regulated products, arresting those responsible, and bringing them before the Department of Justice for prosecution. The Food and Drug Administration (FDA) requires contractor support to further its on-going efforts to counter the widespread illicit trafficking and/or marketing of FDA-regulated products over the Internet.

These products include prescription drugs; dietary supplements; tobacco; medical devices; blood and biologics; vaccines; cosmetics; radiation-emitting products; animal and veterinary medicines; and foods.

## Award on USAspending

- Recipient: S-3 Research LLC (UEI LELZHK767GF3)
- Contract: 75F40124P00395, purchase order
- Obligated: $2,538,016.00
- Competition: Competed Under SAP, 10 offers received
- Link: solicitation number 75F40124Q00348 equals the FPDS solicitation identifier; same sub-agency 7524 (high confidence)
- Record: https://www.usaspending.gov/award/CONT_AWD_75F40124P00395_7524_-NONE-_-NONE-/


## Publications

- July 8, 2024: Combined synopsis and solicitation, due July 18, 2024 at 3:00 PM EDT. Notice 7dadee94a1b746109cbe3df7fc5dea91. https://sam.gov/workspace/contract/opp/7dadee94a1b746109cbe3df7fc5dea91/view
- July 9, 2024: Combined synopsis and solicitation, due July 18, 2024 at 3:00 PM EDT. Notice 91cb00bcb96e41db9e8e1c1b9fbbb4f5. https://sam.gov/workspace/contract/opp/91cb00bcb96e41db9e8e1c1b9fbbb4f5/view
- July 18, 2024: Combined synopsis and solicitation, due July 22, 2024 at 10:00 AM EDT. Notice 4bdede173938452884e7c2d482f729a8. https://sam.gov/workspace/contract/opp/4bdede173938452884e7c2d482f729a8/view
- October 1, 2024: Award notice. Notice 778f8cd9399a48e2ae16075261337c2c. https://sam.gov/workspace/contract/opp/778f8cd9399a48e2ae16075261337c2c/view

## Points of contact

- Brian Wodzisz, Brian.Wodzisz@fda.hhs.gov, 3017967376
- Michelle Dacanay, michelle.dacanay@fda.hhs.gov, 301-796-0447

---
Source: SAM.gov Contract Opportunities bulk extract and USAspending.gov award data. Confirm deadlines on SAM.gov before responding. Cite https://abierto.us/opportunities/75f40124q00348.